Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma
NCT01370135
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Neovascular Glaucoma
Rubeosis
Interventions
DRUG:
0.5mg intraocular Ranibizumab (Lucentis)
Sponsor
University of Luebeck